FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

Medical device FDA 510(k) approvals are still challenging (Weekend Rounds)
Life science current events this week include medical device FDA approvals, a move from University Hospitals Cleveland to Mayo Clinic for Dr. James Levine, and job advice for medical device marketers.